ANNX.ST
Healthcare BiotechnologyAnnexin Pharmaceuticals AB (publ)
SEK 8.76
-0.18 -2.01% today Live
Price History
Not enough data
| Date | Price |
|---|---|
| Oct 7, 2026, live at 2:43 PM ET | 8.76 |
Key Stats
Market Cap
76.37M
Avg Volume
9,287
EPS
-SEK 6.20
52W High
SEK 29.80
52W Low
SEK 8.54
Div. Yield
0.0%
Valuation
P/B Ratio
24.54
EV/EBITDA
-1.41
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(177.5%)
Return on Assets
(90.0%)
Liquidity & Leverage
Current Ratio
1.19
Quick Ratio
1.08
Total Cash
5.27M
Total Debt
0
About
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.
annexinpharma.se